Clinical endpoint (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Clinical endpoint" in English language version.

refsWebsite

Global rank English rank

7nih.gov

4^th place

6doi.org

2^nd place

2cancer.gov

1,684^th place

1,350^th place

2fda.gov

447^th place

338^th place

1uu.nl

2,467^th place

2,049^th place

1web.archive.org

1^st place

1semanticscholar.org

11^th place

8^th place

1mwsug.org

low place

1oncolink.org

low place

cancer.gov

"median overall survival". NCI Dictionary of Cancer Terms. National Cancere Institute. Retrieved 4 December 2014.
"NCI Dictionary of Cancer Terms". National Cancer Institute. Retrieved 5 June 2016.

doi.org

Penninckx, B; Van de Voorde, W M; Casado, A; Reed, N; Moulin, C; Karrasch, M (26 June 2012). "A systemic review of Toxic Death in clinical oncology trials: an Achilles' heel in safety reporting revisited". British Journal of Cancer. 107 (1): 1–6. doi:10.1038/bjc.2012.252. PMC 3389431. PMID 22677904.
Biomarkers Definitions Working Group (March 2001). "Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework". Clinical Pharmacology & Therapeutics. 69 (3): 89–95. doi:10.1067/mcp.2001.113989. PMID 11240971. S2CID 288484.
De Gruttola, Victor G; Clax, Pamela; DeMets, David L; Downing, Gregory J; Ellenberg, Susan S; Friedman, Lawrence; Gail, Mitchell H; Prentice, Ross; Wittes, Janet; Zeger, Scott L (October 2001). "Considerations in the Evaluation of Surrogate Endpoints in Clinical Trials". Controlled Clinical Trials. 22 (5): 485–502. doi:10.1016/S0197-2456(01)00153-2. PMID 11578783.
Cohn, J. N. (29 June 2004). "Introduction to Surrogate Markers". Circulation. 109 (25 suppl 1): IV–20–IV-21. doi:10.1161/01.CIR.0000133441.05780.1d. PMID 15226247.
Handforth, C.; Hall, P.; Marshall, H.; Seymour, M. (October 2013). "Overall treatment utility: A novel outcome measure to convey the balance of benefits and harms from cancer treatment". Journal of Geriatric Oncology. 4: S49. doi:10.1016/j.jgo.2013.09.064.
Core Outcomes in Women's Health (CROWN) Initiative (2014). "The CROWN Initiative: journal editors invite researchers to develop core outcomes in women's health". Journal of Gynecologic Oncology. 25 (3): 166–7. doi:10.3802/jgo.2014.25.3.166. PMC 4102731. PMID 25045427.

fda.gov

accessdata.fda.gov

"CFR - Code of Federal Regulations Title 21". www.accessdata.fda.gov. April 1, 2020. Retrieved 9 January 2021. This article incorporates text from this source, which is in the public domain.

fda.gov

Guidance for Industry Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics FDA

mwsug.org

Objective tumor response and RECIST criteria in cancer clinical trials

nih.gov

pubmed.ncbi.nlm.nih.gov

Penninckx, B; Van de Voorde, W M; Casado, A; Reed, N; Moulin, C; Karrasch, M (26 June 2012). "A systemic review of Toxic Death in clinical oncology trials: an Achilles' heel in safety reporting revisited". British Journal of Cancer. 107 (1): 1–6. doi:10.1038/bjc.2012.252. PMC 3389431. PMID 22677904.
Biomarkers Definitions Working Group (March 2001). "Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework". Clinical Pharmacology & Therapeutics. 69 (3): 89–95. doi:10.1067/mcp.2001.113989. PMID 11240971. S2CID 288484.
De Gruttola, Victor G; Clax, Pamela; DeMets, David L; Downing, Gregory J; Ellenberg, Susan S; Friedman, Lawrence; Gail, Mitchell H; Prentice, Ross; Wittes, Janet; Zeger, Scott L (October 2001). "Considerations in the Evaluation of Surrogate Endpoints in Clinical Trials". Controlled Clinical Trials. 22 (5): 485–502. doi:10.1016/S0197-2456(01)00153-2. PMID 11578783.
Cohn, J. N. (29 June 2004). "Introduction to Surrogate Markers". Circulation. 109 (25 suppl 1): IV–20–IV-21. doi:10.1161/01.CIR.0000133441.05780.1d. PMID 15226247.
Core Outcomes in Women's Health (CROWN) Initiative (2014). "The CROWN Initiative: journal editors invite researchers to develop core outcomes in women's health". Journal of Gynecologic Oncology. 25 (3): 166–7. doi:10.3802/jgo.2014.25.3.166. PMC 4102731. PMID 25045427.

ncbi.nlm.nih.gov

Penninckx, B; Van de Voorde, W M; Casado, A; Reed, N; Moulin, C; Karrasch, M (26 June 2012). "A systemic review of Toxic Death in clinical oncology trials: an Achilles' heel in safety reporting revisited". British Journal of Cancer. 107 (1): 1–6. doi:10.1038/bjc.2012.252. PMC 3389431. PMID 22677904.
Core Outcomes in Women's Health (CROWN) Initiative (2014). "The CROWN Initiative: journal editors invite researchers to develop core outcomes in women's health". Journal of Gynecologic Oncology. 25 (3): 166–7. doi:10.3802/jgo.2014.25.3.166. PMC 4102731. PMID 25045427.

oncolink.org

"Understanding a Cancer Research Study | OncoLink". www.oncolink.org. Retrieved 10 September 2023.

semanticscholar.org

api.semanticscholar.org

Biomarkers Definitions Working Group (March 2001). "Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework". Clinical Pharmacology & Therapeutics. 69 (3): 89–95. doi:10.1067/mcp.2001.113989. PMID 11240971. S2CID 288484.

uu.nl

vet.uu.nl

Humane Endpoints Archived 2010-08-27 at the Wayback Machine From Netherlands Association for Laboratory Animal Science (NVP). Retrieved April 2011.

web.archive.org

Humane Endpoints Archived 2010-08-27 at the Wayback Machine From Netherlands Association for Laboratory Animal Science (NVP). Retrieved April 2011.